Navigation Links
AlphaRx Shareholder Update
Date:6/24/2009

MARKHAM, ON, June 24 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ALRX) releases letter to their shareholders:

Dear Shareholders,

We wanted to take a few minutes to update the current views on AlphaRx. For the first time in our corporate history, we ended our last quarter with a small profit. Aside from the fact that it was a small amount, it was significant on more than one front. The events that occurred over the past few weeks, have woke up investors around the world.

Our revenue is growing and our product pipeline remains robust and stronger than ever. We have 2 partnered products with potential milestone payments in excess of US$ 155 million which may generate a long-term stream of multi-million dollar royalty income. We at AlphaRx, have established research collaborations with leading specialty pharmaceutical companies and research institutions, such as the US Army. We have both benefited either financially or scientifically. Furthermore, these collaborations may lead to licensing agreements of our products.

We are in the forefront of nanomedicine development and we are poised to be the world's first pharmaceutical company to commercialize a polymeric-based nanomedicine for the treatment of nosocomial pneumonia.

Our goal, as it has been from Day number one, is to create profit for our shareholders and increase shareholder value. We believe we are succeeding. Thank you for your support. We will continue to keep you informed.

    Michael M. Lee

    President & CEO

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
2. AlphaRx Signs Cooperative Research and Development Agreement with US Army
3. AlphaRx Provides Corporate and Development Update
4. AlphaRxs Indaflex(TM) Continues its Clinical Development
5. AlphaRx CEO Accumulates More Company Shares
6. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
7. AlphaRx Announces Debt Conversion
8. AlphaRx To Present at 47th Annual ICAAC
9. All Seven Members of RBC Life Sciences Board of Directors Were Re-Elected During the Companys 2009 Annual Shareholders Meeting
10. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
11. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... specialized asset-light logistics provider of complex transport solutions for mission-critical and non-discretionary ... Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. (NYSE: RRTS). ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... devices. Through an educational webinar, they will present the line of epMotion automated ... learn how easy you can automate everyday pipetting tasks. , Ideal for scientists ...
(Date:8/18/2017)... Woodlands, TX (PRWEB) , ... August 18, 2017 ... ... protection assistance and financial planning services to communities in east Texas, is launching ... Pediatric Brain Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... The Golseth ... in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to provide ... , In early June of this year, Christina and her children returned from out ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the body ... with its product now available through Jet.com. , After 25 years of development, ... drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)...  Endo International plc (NASDAQ: ENDP ) ... all known U.S. mesh product liability claims and that ... remaining U.S. claims at reasonable values. Under the agreements, ... quarter of 2017 and continuing through the fourth quarter ... results, the Company intends to increase its mesh product ...
(Date:8/2/2017)... AROMAS, Calif. , Aug. 2, 2017 /PRNewswire/ ... by Continental Who,s Who as a Pinnacle Lifetime ... currently the Key Account Manager at Turing Pharmaceuticals, ... communications, negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience ...
(Date:8/1/2017)... Aug. 1, 2017   CerSci Therapeutics , a ... Texas , has received notice from the National ... of Health (NIH) that it has been awarded a ... over $650,000 in 2017 with an additional $1,000,000 to ... New Drug application of their lead non-opioid drug candidate ...
Breaking Medicine Technology: